The company wants to break into non-small cell lung cancer therapy but is unlikely to score a true hit in its head-to-head with Merck & Co’s blockbuster Keytruda.

Many gene therapies companies have faced R&D and financial problems this year but the longer term potential of the field and low prices might tempt big pharma into deals.

Allogene hopes its off-the-shelf CAR-T can begin a potentially pivotal Phase II study by the end of this year but is frustrated by an “under-resourced and overworked FDA.”

With a new CEO at the helm, Gamida is closing in on an FDA approval, but a lack of cash could hobble its US launch efforts for allogeneic cell therapy product omidubicel.

As the first CRISPR-based therapies draw closer to approval, the Flagship-backed biotech believes its gene writing tech is the ‘definitive’ genetic medicine platform.

GSK has poached its new chief financial officer from fashion brand Burberry, but Julie Brown’s experience at AstraZeneca and Roche will give her insights into how to lead GSK into its next phase.